Arvinas Inc. is developing two small molecule technologies to mark disease-linked proteins for destruction by the proteasome, a cellular garbage disposal system. The company aims to identify an oncology lead from one of its two platforms by late 2014.

Both technologies come from the laboratory of Craig Crews, professor of chemistry, pharmacology and molecular, cellular and developmental biology at Yale University.